Ignite Creation Date:
2024-05-06 @ 7:16 PM
Last Modification Date:
2024-10-26 @ 3:03 PM
Study NCT ID:
NCT05950308
Status:
COMPLETED
Last Update Posted:
2023-07-18
First Post:
2023-07-14
Brief Title:
Assessment of Immune Response in Multiple Sclerosis Patients With COVID-19Vaccination Treated With Ofatumumab and Other Disease Modifying Therapies
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
Assessment of Immune Response in Multiple Sclerosis Patients With COVID-19Vaccination Treated With Ofatumumab and Other Disease Modifying Therapies
Status:
COMPLETED
Status Verified Date:
2023-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Vaccine responses in patients treated with anti-CD20 antibodies ocrelizumab and ofatumumab or S1P receptor modulators fingolimod and siponimod were evaluated before and after third SARS-CoV-2 vaccination as part of an ongoing longitudinal study Total spike protein and spike receptor binding domain RBD-specific immunoglobulin G IgG responses were measured by Luminex bead-based assay Spike-specific CD4 and CD8 T cell responses were measured by activation-induced marker expression
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None